ATE234095T1 - Produkt enthaltend rapamycin oder ausgewählte derivate und einen nmda- oder ampa-antagonisten zur verwendung für die behandlung von epilepsie oder morbus huntington, und die verwendung von rapamycin oder von ausgewählten derivaten für die herstellung eines medikaments für die behandlung von epilepsie oder morbus huntington. - Google Patents
Produkt enthaltend rapamycin oder ausgewählte derivate und einen nmda- oder ampa-antagonisten zur verwendung für die behandlung von epilepsie oder morbus huntington, und die verwendung von rapamycin oder von ausgewählten derivaten für die herstellung eines medikaments für die behandlung von epilepsie oder morbus huntington.Info
- Publication number
- ATE234095T1 ATE234095T1 AT96308786T AT96308786T ATE234095T1 AT E234095 T1 ATE234095 T1 AT E234095T1 AT 96308786 T AT96308786 T AT 96308786T AT 96308786 T AT96308786 T AT 96308786T AT E234095 T1 ATE234095 T1 AT E234095T1
- Authority
- AT
- Austria
- Prior art keywords
- huntington
- epilepsy
- treatment
- disease
- rapamycin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US833795P | 1995-12-07 | 1995-12-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE234095T1 true ATE234095T1 (de) | 2003-03-15 |
Family
ID=21731060
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT96308786T ATE234095T1 (de) | 1995-12-07 | 1996-12-04 | Produkt enthaltend rapamycin oder ausgewählte derivate und einen nmda- oder ampa-antagonisten zur verwendung für die behandlung von epilepsie oder morbus huntington, und die verwendung von rapamycin oder von ausgewählten derivaten für die herstellung eines medikaments für die behandlung von epilepsie oder morbus huntington. |
Country Status (23)
Country | Link |
---|---|
EP (1) | EP0778023B1 (de) |
JP (1) | JPH09183727A (de) |
KR (1) | KR970032856A (de) |
CN (1) | CN1112925C (de) |
AR (1) | AR008747A1 (de) |
AT (1) | ATE234095T1 (de) |
AU (1) | AU700653B2 (de) |
BR (1) | BR9605895A (de) |
CA (1) | CA2192298A1 (de) |
CZ (2) | CZ6498A3 (de) |
DE (1) | DE69626610T2 (de) |
DK (1) | DK0778023T3 (de) |
ES (1) | ES2188730T3 (de) |
HU (1) | HUP9603370A3 (de) |
IL (1) | IL119778A (de) |
MX (1) | MX9606131A (de) |
NO (1) | NO309966B1 (de) |
NZ (1) | NZ299888A (de) |
PT (1) | PT778023E (de) |
SI (1) | SI0778023T1 (de) |
SK (1) | SK154796A3 (de) |
TW (1) | TW427904B (de) |
ZA (1) | ZA9610245B (de) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1002535A1 (de) | 1998-10-28 | 2000-05-24 | Hrissanthi Ikonomidou | Neue Verwendung von Glutamat-Antagonisten zur Behandlung von Krebs |
US6417189B1 (en) * | 1999-11-12 | 2002-07-09 | Gpi Nil Holdings, Inc. | AZA compounds, pharmaceutical compositions and methods of use |
US7253169B2 (en) | 1999-11-12 | 2007-08-07 | Gliamed, Inc. | Aza compounds, pharmaceutical compositions and methods of use |
FR2806626B1 (fr) * | 2000-03-22 | 2003-11-28 | Centre Nat Rech Scient | Utilisation de substances modulatrices de l'expression ou de la fonction d'une proteine impliquee dans le cycle cellulaire pour le traitement ou la prevention des lesions neurales aigues |
AU2001255406A1 (en) * | 2000-04-17 | 2001-10-30 | Gpi Nil Holdings, Inc. | Cyclic diaza compounds for treating neurodegenerative disorders |
GB0117645D0 (en) * | 2001-07-19 | 2001-09-12 | Isis Innovation | Therapeutic stratergies for prevention and treatment of alzheimers disease |
UA78529C2 (en) | 2001-10-10 | 2007-04-10 | Wyeth Corp | Derivatives of [[2-(amino-3,4-dioxo-1-cyclobutene-1-yl)amino]alkyl] acid for treating pain |
US20030176455A1 (en) * | 2002-03-13 | 2003-09-18 | Wyeth | Method of inhibiting cell death |
EP1622625A1 (de) * | 2003-04-09 | 2006-02-08 | Wyeth | Pharmazeutische zusammensetzungen für die intranasale verabreichung von [2-(8,9-dioxo-2,6-diazabicyclo [5.2.0] non-1 (7)-en-2-yl)alkyl] phosphonsäure und derivaten und anwendungsverfahren dafür |
EP1611144B1 (de) | 2003-04-09 | 2010-09-15 | Wyeth LLC | Derivate von 2-(8,9-dioxo-2,6-diazabicyclo(5.2.0)non-1(7)-en-2-yl)alkylphosphonsäure und deren verwendung als n-methyl-d-aspartat- (nmda-) rezeptorantagonisten |
WO2004089369A2 (en) * | 2003-04-11 | 2004-10-21 | Cambridge University Technical Services Limited | Methods and means for treating protein conformational disorders |
US7485706B2 (en) * | 2003-07-30 | 2009-02-03 | The Board Of Trustees Of The Leland Stanford Junior University | Neurodegenerative protein aggregation inhibition methods and compounds |
GT200400213A (es) | 2003-10-22 | 2007-09-05 | Metodos para la preparacion del acido {2-[(8,9)-dioxo-2,6-diaza-biciclo[5.2.0]-non-1(7)-en-2-il]etil} fosfonico y esteres del mismo | |
DK1828202T3 (da) * | 2004-12-20 | 2012-05-07 | Wyeth Llc | Rapamycinanaloge samt deres anvendelse ved behandling af neurologiske, proliferative og inflammatoriske lidelser |
US7273874B2 (en) | 2004-12-20 | 2007-09-25 | Wyeth | Rapamycin derivatives and the uses thereof in the treatment of neurological disorders |
JP4857071B2 (ja) * | 2006-10-12 | 2012-01-18 | 潤平 笹部 | 筋萎縮性側策硬化症(als)の検出方法 |
EP2065038A1 (de) | 2007-11-30 | 2009-06-03 | Pharnext | Neue therapeutische Ansätze zur Behandlung der Charcot-Marie-Tooth Krankheit |
EP2135607A1 (de) | 2008-06-18 | 2009-12-23 | Pharnext | Kombination aus Pilocarpin und Methimazol zur Behandlung der Charcot-Marie-Tooth Krankheit und verwandten Erkrankungen |
KR20130128018A (ko) * | 2009-04-10 | 2013-11-25 | 하이얀 치 | 새로운 노화 방지 물질 및 그 확인 방법 |
US9393241B2 (en) | 2009-06-02 | 2016-07-19 | Pharnext | Compositions for treating CMT and related disorders |
EP2263665A1 (de) | 2009-06-02 | 2010-12-22 | Pharnext | Neue Zusammensetzungen zur Behandlung von CMT und verwandten Erkrankungen |
EP2456437A4 (de) * | 2009-07-24 | 2013-01-09 | Inst Nat Rech Scient | Kombinationen aus curcumoiden- und mtor-hemmern für die behandlung von tauopathien |
US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
US9121859B2 (en) * | 2012-12-04 | 2015-09-01 | Siemens Healthcare Diagnostics Inc. | Compounds and methods for determination of FKBP-binding immunosuppressant drugs |
LT3003268T (lt) | 2013-06-05 | 2018-12-10 | Pharnext | Stabilūs peroraliniai tirpalai, skirti kompleksiniam aktyviam farmaciniam ingredientui (api) |
US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
US10383870B2 (en) | 2016-06-10 | 2019-08-20 | Pharnext | Early treatment of CMT disease |
WO2019099671A1 (en) * | 2017-11-15 | 2019-05-23 | Vanderbilt University | Methods and compositions for the improvement of lysosomal function and treatment of neurodegenerative disease |
CN114366738A (zh) * | 2021-12-20 | 2022-04-19 | 中国人民解放军军事科学院军事医学研究院 | 雷帕霉素在促进神经干细胞扩增中的用途 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5206018A (en) * | 1978-11-03 | 1993-04-27 | Ayerst, Mckenna & Harrison, Inc. | Use of rapamycin in treatment of tumors |
JPH04230389A (ja) * | 1990-07-16 | 1992-08-19 | American Home Prod Corp | ラパマイシン誘導体 |
US5078999A (en) * | 1991-02-22 | 1992-01-07 | American Home Products Corporation | Method of treating systemic lupus erythematosus |
IL101353A0 (en) * | 1991-04-03 | 1992-11-15 | American Home Prod | Pharmaceutical compositions for treating diabetes |
DE4118740A1 (de) * | 1991-06-05 | 1992-12-10 | Schering Ag | Neue kombinationspraeparate zur behandlung des morbus parkinson |
ZA924953B (en) * | 1991-07-25 | 1993-04-28 | Univ Louisville Res Found | Method of treating ocular inflammation |
US5260299A (en) * | 1992-03-05 | 1993-11-09 | American Home Products Corporation | Rapamycin 42-sulfonates and 42-(N-Carboalkoxy)Sulfamates Useful as Immunosuppressive Agents |
IL111003A0 (en) * | 1993-09-30 | 1994-11-28 | American Home Prod | Multi-component oral rapamycin formulation |
-
1996
- 1996-11-28 TW TW085114700A patent/TW427904B/zh not_active IP Right Cessation
- 1996-12-04 DE DE69626610T patent/DE69626610T2/de not_active Expired - Fee Related
- 1996-12-04 EP EP96308786A patent/EP0778023B1/de not_active Expired - Lifetime
- 1996-12-04 ES ES96308786T patent/ES2188730T3/es not_active Expired - Lifetime
- 1996-12-04 DK DK96308786T patent/DK0778023T3/da active
- 1996-12-04 CZ CZ9864A patent/CZ6498A3/cs unknown
- 1996-12-04 SK SK1547-96A patent/SK154796A3/sk unknown
- 1996-12-04 SI SI9630586T patent/SI0778023T1/xx unknown
- 1996-12-04 CZ CZ963544A patent/CZ354496A3/cs unknown
- 1996-12-04 AT AT96308786T patent/ATE234095T1/de not_active IP Right Cessation
- 1996-12-04 PT PT96308786T patent/PT778023E/pt unknown
- 1996-12-05 MX MX9606131A patent/MX9606131A/es unknown
- 1996-12-05 KR KR1019960062011A patent/KR970032856A/ko not_active Application Discontinuation
- 1996-12-05 ZA ZA9610245A patent/ZA9610245B/xx unknown
- 1996-12-05 AU AU74178/96A patent/AU700653B2/en not_active Ceased
- 1996-12-05 NZ NZ299888A patent/NZ299888A/en unknown
- 1996-12-06 CN CN96123098A patent/CN1112925C/zh not_active Expired - Fee Related
- 1996-12-06 AR ARP960105543A patent/AR008747A1/es not_active Application Discontinuation
- 1996-12-06 NO NO965238A patent/NO309966B1/no not_active IP Right Cessation
- 1996-12-06 IL IL11977896A patent/IL119778A/xx not_active IP Right Cessation
- 1996-12-06 JP JP8326582A patent/JPH09183727A/ja active Pending
- 1996-12-06 CA CA002192298A patent/CA2192298A1/en not_active Abandoned
- 1996-12-06 BR BR9605895A patent/BR9605895A/pt not_active Application Discontinuation
- 1996-12-06 HU HU9603370A patent/HUP9603370A3/hu unknown
Also Published As
Publication number | Publication date |
---|---|
DK0778023T3 (da) | 2003-06-30 |
IL119778A (en) | 1999-07-14 |
CN1159915A (zh) | 1997-09-24 |
MX9606131A (es) | 1997-08-30 |
CZ354496A3 (cs) | 1998-03-18 |
JPH09183727A (ja) | 1997-07-15 |
ZA9610245B (en) | 1998-06-05 |
SK154796A3 (en) | 1997-09-10 |
PT778023E (pt) | 2003-06-30 |
CZ6498A3 (cs) | 1998-06-17 |
NO309966B1 (no) | 2001-04-30 |
BR9605895A (pt) | 1998-08-18 |
TW427904B (en) | 2001-04-01 |
AU7417896A (en) | 1997-06-12 |
ES2188730T3 (es) | 2003-07-01 |
NZ299888A (en) | 2001-02-23 |
EP0778023A1 (de) | 1997-06-11 |
CN1112925C (zh) | 2003-07-02 |
DE69626610T2 (de) | 2003-10-02 |
AR008747A1 (es) | 2000-02-23 |
SI0778023T1 (en) | 2003-08-31 |
DE69626610D1 (de) | 2003-04-17 |
CA2192298A1 (en) | 1997-06-08 |
HUP9603370A3 (en) | 1998-12-28 |
IL119778A0 (en) | 1997-03-18 |
NO965238D0 (no) | 1996-12-06 |
HUP9603370A2 (en) | 1997-05-28 |
HU9603370D0 (en) | 1997-01-28 |
EP0778023B1 (de) | 2003-03-12 |
AU700653B2 (en) | 1999-01-14 |
KR970032856A (ko) | 1997-07-22 |
NO965238L (no) | 1997-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE234095T1 (de) | Produkt enthaltend rapamycin oder ausgewählte derivate und einen nmda- oder ampa-antagonisten zur verwendung für die behandlung von epilepsie oder morbus huntington, und die verwendung von rapamycin oder von ausgewählten derivaten für die herstellung eines medikaments für die behandlung von epilepsie oder morbus huntington. | |
DE3855525T2 (de) | Verwendung eines Protein gebundenen Polysaccharid Zur Herstellung eines Arzneimittels für die Behandlung von AIDS. | |
DE69621602T2 (de) | Verschluss mit erhöhter flexibilität, verfahren und vorrichtung für dessen herstellung und so hergestelltes produkt | |
DE69310065T2 (de) | Verwendung von 2-(3,4-Dimethoxycinnamoyl)aminobenzoesäure zur Herstellung eines Arzeimittels zur Behandlung der Restenose | |
DE3870376D1 (de) | Blattfoermiges material zur haut- oder haarbehandlung, verfahren zu dessen herstellung und aus diesem material hergestellte gegenstaende. | |
DE69626961T2 (de) | Wegwerfkleidungsstück, verfahren und vorrichtung zu dessen herstellung | |
DE69706566T2 (de) | Verwendung von dem chelatbildner clioquinol zur herstellung eines arzneimittelszur behandlung von alzheimerschen krankheit | |
ATE335487T1 (de) | Verwendung von pyridazino 4,5-(b)ö-indole-1- acetamide derivaten zur herstellung eines arzneimittels zur behandlung von durch periphere benzodiazepinrezeptoren-störungen verursachte krankheiten | |
DE69426320T2 (de) | Verwendung von silikon/fluorsilikon kopolymeröl zur herstellung eines arzneimittels zur behandlung von augenerkrankungen | |
DE69925488D1 (de) | Verwendung von fk506 und verwandten makroliden zur herstellung eines medikaments für die behandlung und vorbeugung von schmerzen | |
ATE212034T1 (de) | Derivate von 5-0-desosaminyl-6-0-methyl erythronolid a, ihre verfahren zur herstellung und verwendung zur herstellung von arzneimitteln | |
DE69623319D1 (de) | Milchprodukt und verfahren zu dessen herstellung | |
DE3768150D1 (de) | Verwendung eines 1,3-oxazolidin-2-on-derivates zur herstellung eines arzneimittels zur behandlung von ischaemie. | |
DE69512977D1 (de) | Material für die Behandlung von Tierexkrementen und Verfahren zu dessen Herstellung | |
DE69620786D1 (de) | Verwendung von cholinesterase-inhibitoren für die herstellung eines medikaments zur behandlung von xerostomie | |
DE69003960T2 (de) | Die Verwendung von deacetyliertem Chitin zur Herstellung eines Medikamentes für die Behandlung von entzündliche Krankheiten. | |
ATE263565T1 (de) | Verwendung von 8,9-dehydroestron zur herstellung eines arzneimittels zur behandlung von durch freie radikale verursachte krankheiten | |
ATE192650T1 (de) | Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit | |
DE69915848D1 (de) | Verwendung von neohesperidin dc zur herstellung eines medikaments zur vorbeugung bzw. behandlung von krankheiten aufgrund erhoehter blutfettwerte | |
DE3483944D1 (de) | Verwendung von selektiv peripheren dopamin-antagonisten zur herstellung eines arzneimittels zur topischen behandlung von okularer hypertension. | |
DE69611253D1 (de) | Verfahren und zwischenprodukte für die herstellung von 3-(1-piperazinyl)-1,2-benzisothiazolen | |
ATE186640T1 (de) | Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung neurogenerativer erkrankungen | |
ATE230988T1 (de) | Die verwendung von ondansetron zur herstellung eines medikamentes zur behandlung von tremor | |
ATE245982T1 (de) | Verwendung von 2-amino-6- trifluoromethoxybenzothiazol zur herstellung eines arzneimittels zur vorbeugung oder behandlung von zerebellumkrankheiten | |
HK1009938A1 (en) | Product comprising rapamycin or particular derivatives and an nmda or ampa antagonist for use for the treatment of epilepsy or huntington's disease, and the use of rapamycin or particular derivatives for the manufacture of a medicament for the treatment of epilepsy or huntington's disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 0778023 Country of ref document: EP |
|
REN | Ceased due to non-payment of the annual fee |